Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARIPIPRAZOLE vs FIORINAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.
FIORINAL is a combination of butalbital (barbiturate), aspirin (NSAID), and caffeine. Butalbital potentiates GABA-A receptor activity, producing sedative-hypnotic effects. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and antipyretic effects. Caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy.
Schizophrenia,Acute manic and mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Adjunctive treatment of major depressive disorder,Irritability associated with autistic disorder,Tourette's disorder
Relief of tension-type headache,Relief of migraine headache (off-label)
Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.
1-2 capsules (butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
Aripiprazole has a terminal elimination half-life of approximately 75 hours in extensive CYP2D6 metabolizers and about 146 hours in poor metabolizers. The active metabolite, dehydro-aripiprazole, has a half-life of about 94 hours. This long half-life allows for once-daily dosing and gradual achievement of steady state (14 days in extensive metabolizers).
Butalbital 35-50 hours, aspirin 15-20 minutes (salicylate 2-3 hours at low doses, >20 hours at high doses), caffeine 3-5 hours. Prolonged in hepatic/renal impairment.
Primarily hepatic via CYP2D6 and CYP3A4.
Butalbital is extensively metabolized in the liver via hydroxylation and glucuronidation, primarily by CYP2C9 and CYP2C19. Aspirin is hydrolyzed to salicylic acid, then conjugated with glycine (salicyluric acid) and glucuronidated. Caffeine is metabolized by CYP1A2 to paraxanthine, theobromine, and theophylline.
Aripiprazole is extensively metabolized primarily by the liver via CYP2D6 and CYP3A4. Approximately 25% of the dose is excreted unchanged in urine, and about 55% in feces. The major metabolite, dehydro-aripiprazole, accounts for about 40% of the AUC and is also excreted in urine and feces.
Renal: 60% butalbital (mostly unchanged), 10% aspirin (salicylates, majorly as metabolites), 3% caffeine (metabolites and unchanged). Fecal: <5% overall.
Aripiprazole is >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. High protein binding means that changes in protein levels (e.g., hypoalbuminemia) can affect free drug concentration.
Butalbital 20-40% (albumin), aspirin 80-90% (albumin, concentration-dependent), caffeine 25-36% (albumin).
The volume of distribution (Vd) for aripiprazole is approximately 4.9 L/kg, indicating extensive tissue distribution (well beyond total body water). This large Vd suggests significant partitioning into tissues, which contributes to the long half-life.
Butalbital 0.8 L/kg, aspirin 0.15-0.2 L/kg, caffeine 0.6-0.8 L/kg. Indicates extensive tissue distribution for butalbital and caffeine.
Oral: The absolute bioavailability of aripiprazole tablets is approximately 87%. Bioavailability is not significantly affected by food. Intramuscular immediate-release: Bioavailability is 100% for the IM formulation relative to oral. The long-acting injectable (aripiprazole lauroxil) has a bioavailability of about 100% compared to oral aripiprazole after reaching steady state.
Oral: butalbital ~100%, aspirin 50-75% (first-pass metabolism), caffeine ~100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). For severe renal impairment (Cr Cl <15 m L/min), use with caution; limited data suggests no adjustment needed, but monitor tolerability.
No specific guidelines; contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to acetaminophen accumulation. Use with caution in moderate impairment.
Child-Pugh Class A (mild): no adjustment. Child-Pugh Class B (moderate): start at 10 mg/day; titrate cautiously. Child-Pugh Class C (severe): avoid use; if unavoidable, start at 5 mg/day and titrate slowly.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). For mild to moderate (Child-Pugh A or B), reduce dose by 50% or extend dosing interval.
Schizophrenia (≥13 years): 10-15 mg/day initially; target 15 mg/day; max 30 mg/day. Irritability associated with autistic disorder (6-17 years): 5-10 mg/day; start at 2.5 mg/day for ≥30 kg and 5 mg/day for <30 kg; titrate gradually. Tourette's disorder (6-18 years): 5-10 mg/day; start at 2.5 mg/day for <50 kg and 5 mg/day for ≥50 kg; max 10 mg/day.
Not recommended for pediatric use; safety and efficacy not established.
Initiate at 10 mg/day; titrate slowly due to increased sensitivity and risk of hypotension, sedation, and extrapyramidal symptoms. Maximum 15 mg/day in elderly patients with psychosis. Consider lower initial doses (2-5 mg/day) in frail patients.
Start at lowest effective dose (e.g., 1 capsule every 4 hours) due to increased sensitivity to butalbital (sedation, confusion) and risk of acetaminophen hepatotoxicity; maximum daily acetaminophen dose 2 g.
Increased risk of death in elderly patients with dementia-related psychosis.
None.
Increased risk of cerebrovascular events in elderly with dementia, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, cognitive and motor impairment, and body temperature dysregulation.
Risk of Reye's syndrome in children with viral illness,Aspirin hypersensitivity (e.g., asthma, nasal polyps),Gastrointestinal bleeding and ulceration,Hepatic impairment due to butalbital metabolism,Caffeine overdose from excessive use,Dependence and withdrawal with prolonged butalbital use
Hypersensitivity to aripiprazole or any components of the formulation.
Hypersensitivity to butalbital, aspirin, or caffeine,Active peptic ulcer disease,Hemophilia or bleeding disorders,Concomitant use of anticoagulants,Children with chickenpox or influenza-like symptoms (risk of Reye's syndrome),Severe hepatic or renal impairment,Porphyria
No significant food interactions. Absorption unaffected by food. Avoid grapefruit juice as it may increase aripiprazole levels via CYP3A4 inhibition.
Avoid excessive caffeine intake from coffee, tea, energy drinks, or chocolate as it may compound caffeine's stimulant effects and increase anxiety or insomnia. Alcohol should be strictly avoided due to additive CNS depression and increased GI bleeding risk with aspirin. No specific food restrictions besides moderation of caffeine-containing foods.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses, but increased risk of neural tube defects at high doses. Second/third trimesters: Possible risk of extrapyramidal symptoms or withdrawal in neonates; risk of gestational diabetes and weight gain. Overall, not a major human teratogen but risk-benefit assessment required.
First trimester: Butalbital is associated with neural tube defects, cleft palate; aspirin increases risk of gastroschisis, cardiac defects. Second trimester: Aspirin may cause premature closure of ductus arteriosus. Third trimester: Aspirin increases risk of intracranial hemorrhage, premature closure of ductus arteriosus; butalbital may cause neonatal withdrawal. Caffeine is not a major teratogen but high doses may increase miscarriage risk.
Aripiprazole is excreted into breast milk; estimated relative infant dose is 1-8% of maternal weight-adjusted dose. M/P ratio not established. Monitor infant for sedation, poor feeding, and extrapyramidal symptoms. Consider benefits of breastfeeding vs. potential risks.
Aspirin excreted in milk (M/P ratio ~0.03-0.3); risk of Reye syndrome. Butalbital excreted in low amounts; may cause neonatal sedation. Caffeine excreted (M/P ~0.5-0.7); may cause irritability. Avoid breastfeeding during chronic use.
Increased clearance and volume of distribution in pregnancy may necessitate dose increases, especially in the third trimester. Therapeutic drug monitoring if available; adjust based on clinical response and tolerability. Postpartum, reduce to prepregnancy dose to avoid toxicity.
Due to increased renal clearance and volume of distribution, butalbital may require dose increase; aspirin may need higher doses due to increased plasma volume; no specific adjustment for caffeine. Monitor clinical response and toxicity.
Aripiprazole is a partial dopamine agonist, distinguishing it from typical antipsychotics. Monitor for akathisia, especially during titration. QT prolongation risk is lower than with other antipsychotics, but ECG is recommended in patients with cardiac risk. Tardive dyskinesia risk exists but may be lower than with typical agents. Avoid abrupt discontinuation to prevent withdrawal dyskinesias. Metabolized by CYP2D6 and CYP3A4; dose adjustments needed with CYP2D6 inhibitors or poor metabolizers. May cause orthostatic hypotension; titrate slowly. Weight gain and metabolic effects are less pronounced than with olanzapine or clozapine, but still monitor weight, lipids, and glucose.
FIORINAL (butalbital/aspirin/caffeine) is a barbiturate-containing combination analgesic. Due to butalbital's high abuse potential and risk of withdrawal, it is reserved for tension-type headaches refractory to non-barbiturate therapies. Monitor for signs of barbiturate dependence, and limit quantity dispensed. Avoid in patients with porphyria, severe hepatic impairment, or hemorrhagic disorders (aspirin component). Caffeine may exacerbate anxiety or insomnia.
Take once daily without regard to meals. Swallow tablets whole, do not crush or chew.,May cause dizziness or drowsiness, especially when starting; avoid driving until you know how it affects you.,Do not stop taking suddenly without consulting your doctor, as this may cause withdrawal symptoms.,Report any restlessness, muscle stiffness, fever, or unusual movements to your doctor immediately.,Limit alcohol intake as it can increase side effects like drowsiness.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double up.,Regular blood tests may be needed to check for effects on blood sugar and cholesterol.
This medication contains butalbital, which can be habit-forming; do not exceed prescribed dose or duration.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and respiratory depression risk.,Do not drive or operate heavy machinery until you know how this drug affects you.,Take with food to reduce stomach upset; if you experience black or bloody stools, stop and seek immediate medical attention (signs of GI bleeding from aspirin).,Do not use more than directed; sudden discontinuation can cause withdrawal symptoms (anxiety, tremors, seizures).,Keep out of reach of children; overdose may be fatal.
"Aripiprazole, a partial dopamine D2 and serotonin 5-HT1A agonist, may have its adverse effects potentiated by methsuximide, a succinimide anticonvulsant that inhibits CYP3A4. This can lead to increased aripiprazole plasma concentrations, raising the risk of extrapyramidal symptoms, sedation, and QT prolongation. Clinical outcomes include heightened neurotoxicity and potential for arrhythmias."
"Concurrent use of aripiprazole and clonazepam increases the risk of central nervous system (CNS) depression, including excessive sedation, dizziness, ataxia, and impaired cognitive or motor function. This additive pharmacodynamic interaction results from the combined depressant effects on the CNS mediated by GABAergic potentiation from clonazepam and dopaminergic/serotonergic modulation from aripiprazole. Patients may experience heightened somnolence, psychomotor slowing, and an increased risk of falls, particularly during initiation or dose escalation."
"Aripiprazole, an atypical antipsychotic with partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at 5-HT2A receptors, can induce orthostatic hypotension, particularly during initial titration. This hypotensive effect may be additive when combined with moexipril, an ACE inhibitor that lowers blood pressure by inhibiting angiotensin II production. Concomitant use increases the risk of symptomatic hypotension, including dizziness, syncope, and falls, especially in elderly or volume-depleted patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARIPIPRAZOLE vs FIORINAL, answered by our medical review team.
ARIPIPRAZOLE is a Atypical Antipsychotic that works by Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.. FIORINAL is a Barbiturate Analgesic Combination that works by FIORINAL is a combination of butalbital (barbiturate), aspirin (NSAID), and caffeine. Butalbital potentiates GABA-A receptor activity, producing sedative-hypnotic effects. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and antipyretic effects. Caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARIPIPRAZOLE and FIORINAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARIPIPRAZOLE is: Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.. The standard adult dose of FIORINAL is: 1-2 capsules (butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARIPIPRAZOLE and FIORINAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARIPIPRAZOLE is classified as Category A/B. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses, but increased risk of neural tube defects at high doses. Second/third trimesters: P. FIORINAL is classified as Category C. First trimester: Butalbital is associated with neural tube defects, cleft palate; aspirin increases risk of gastroschisis, cardiac defects. Second trimester: Aspirin may cause prem. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.